Ventilatory requirements of quadriceps resistance training in people with COPD and healthy controls
Authors Houchen-Wolloff L, Sandland C, Harrison S, Menon M, Morgan M, Steiner M, Singh S
Received 13 December 2013
Accepted for publication 24 January 2014
Published 5 June 2014 Volume 2014:9(1) Pages 589—595
Checked for plagiarism Yes
Review by Single-blind
Peer reviewer comments 3
Linzy Houchen-Wolloff,1 Carolyn J Sandland,1 Samantha L Harrison,1 Manoj K Menon,1 Mike D Morgan,1 Michael C Steiner,1 Sally J Singh1,2
1Centre for Exercise and Rehabilitation Science, Respiratory Biomedical Research Unit, Glenfield Hospital, Leicester, UK; 2Faculty of Health and Life Sciences, Coventry University, Coventry, UK
Background: It is proposed that resistance training (RT) does not activate the cardiopulmonary system to the same extent as whole-body exercise. This is important for patients with chronic obstructive pulmonary disease (COPD) who are ventilatory limited.
Objective: The aim was to assess the ventilatory response to an isokinetic quadriceps RT program in people with COPD and healthy controls.
Registration number: ISRCTN22764439.
Setting: Outpatient, university teaching hospital.
Participants and outcome measures: People with COPD (n=14) and healthy controls (n=11) underwent breath-by-breath analysis of their ventilation during an RT session (five sets of 30 maximal knee extensions at 180°/sec). Subjects performed a maximal cycle ergometry test (CET) at baseline. Peak ventilation (VE; L/min) and oxygen consumption (VO2; mL/kg/min) were collected. The same system measured VO2 and VE during the RT session. Parameters are presented as a percentage of the maximal CET. Isokinetic workload, symptom scores, heart rate (HR), and oxygen saturation were documented post-training.
Results: People with COPD worked at higher percentages of their maximal capacity than controls (mean range between sets 1–5 for VO2 =49.1%–60.1% [COPD], 45.7%–51.43% [controls] and for VE =57.6%–72.2% [COPD], 49.8%–63.6% [controls]), although this was not statistically significant (P>0.1 in all cases). In absolute terms, the difference between groups was only significant for actual VO2 on set 2 (P<0.05). Controls performed more isokinetic work than patients with COPD (P<0.05). Median Borg symptom scores after RT were the same in both groups (3 breathlessness, 13 exertion), no de-saturation occurred, and both groups were training at ≥65% of their maximum HR.
Conclusion: No statistically significant differences were found between people with COPD and healthy controls for VO2 and VE achieved during training. The symptoms associated with training were within acceptable limits.
Keywords: exercise, ventilation, strength training, resistance training
This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.Download Article [PDF] View Full Text [HTML][Machine readable]
Other article by this author:
Survival following pulmonary rehabilitation in patients with COPD: the effect of program completion and change in incremental shuttle walking test distance
Houchen-Wolloff L, Williams JEA, Green RH, Woltmann G, Steiner MC, Sewell L, Morgan MD, Singh SJ
Published Date: 20 December 2017
Readers of this article also read:
Ferzoco RM, Ruddy KJ
Published Date: 23 November 2015
Zhu XC, Zhang JL, Ge CT, Yu YY, Wang P, Yuan TF, Fu CY
Published Date: 18 August 2015
Published Date: 5 August 2015
Published Date: 6 May 2015
Erickson LA, Highsmith Jr WE, Fei P, Zhang J
Published Date: 8 April 2015
Weiss J, Stephenson BJ, Edwards LJ, Rigney M, Copeland A
Published Date: 16 July 2014
Doufekas K, Olaitan A
Published Date: 23 May 2014
Should a Toll-like receptor 4 (TLR-4) agonist or antagonist be designed to treat cancer? TLR-4: its expression and effects in the ten most common cancers
Mai CW, Kang YB, Pichika MR
Published Date: 5 November 2013
Shen L, Cui J, Liang S, Pang Y, Liu P
Published Date: 4 April 2013
Published Date: 5 December 2012